Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Intercell Buys Vaccines Firm

May 19, 2008 | A version of this story appeared in Volume 86, Issue 20

Intercell will acquire the Gaithersburg, Md.-based vaccine firm Iomai in an all-stock deal valued at $189 million. Intercell says the purchase will diversify its vaccine portfolio, expanding its pipeline by three clinical and three preclinical vaccine candidates. In the deal, Iomai contributes an immunostimulant vaccine patch in Phase II trials for pandemic flu and a vaccine for traveler's diarrhea that is slated to enter Phase III trials in the first half of next year. Intercell says the traveler's diarrhea vaccine will complement its Japanese encephalitis vaccine, which is currently under FDA review. Intercell also gains needle-free vaccine delivery technology that it plans to apply to other vaccines in its development pipeline.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.